LUNG (39) SKYA (42) STIM (30) PYPD (44) ⌘ Pro Terminal →

KORU Medical Systems Inc. (KRMD) — RQD Stock Rating Cockpit

$2.99 -7.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.94

KORU Medical Systems Inc. (KRMD) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $149.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KRMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, KORU Medical Systems Inc. (NASDAQ: KRMD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $2.99 (-7.43% 1D, market cap $149.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, KRMD ranks #413 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KRMD compare to LUNG and SKYA in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), KRMD carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of -28.7%. By comparison, LUNG (Pulmonx Corporation) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $135.9M) and SKYA (SkyAI Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $126.7M). Among the 5-stock peer group, KRMD leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KRMD?

▼

Per KRMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000704440), KORU Medical Systems Inc. generated $41.1M in revenue (+22.2% YoY), -$2.6M in net income, and $462.4K in free cash flow against $28.2M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.94 (-1.53%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KRMD)Realized 20D OHLCV Swing Band: ±9.2%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY KRMD SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (36% of score)

Altman Z-Score 8.05 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 1.1% FCF Margin ($462.4K FCF) & 62.3% Gross Margin

▼ #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)

Macro rate sensitivity & RSI-14 (55.8) create a -15 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.97+1.7% Next Q

Q2 (-2Q)

Grade D$3.02+3.3% Next Q

Q3 (-1Q)

Grade D$3.12-4.2% Next Q

Current

Grade D$2.99-6.3% Hist 90D α

Trajectory: E (37) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KRMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KRMD currently carries a cautious 45/100 (D) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.13) and Max Pain ($3.14) forces dealer call-delta covering toward $6.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KRMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KRMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

55.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

8.05>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE3% OF RANGE

L: $3$2.99H: $7

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on KRMD

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

-28.7% ROIC with 62.3% gross margin and 0.31% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (80)

Altman-Z 8.05 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (32)

14/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like KRMD

✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KRMD)

✓Walkthrough of KRMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KRMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -25.06%▼ DESCENDING CHANNEL

2026-11-02O $3.22H $3.23L $2.99C $2.99VOL 84.3K

RES: $3.30SUP: $2.66SMA50: $3.13SMA200: $4.01

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KRMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KRMD Butterfly Map → + Track KRMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KRMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KRMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KRMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KRMD)

Health Care Rank #413 of 1016 ⚔️ LUNG vs KRMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KRMD vs. LUNG, SKYA, STIM, PYPD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, KORU Medical Systems Inc. (KRMD) ranks #413 by composite RQD confidence (45/100, grade D) and #610 by equity capitalization ($149.1M). Within this direct 5-issuer industry benchmark cohort, KRMD leads on earnings valuation at N/A trailing P/E, while KRMD leads on capital efficiency and profitability with -28.7% ROIC and 62.3% gross margin. KRMD currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KRMD ACTIVE KORU Medical Systems Inc.	D	45/100	—	62.3%	-28.7%	-7.43%	$149.1M	Benchmark Subject
LUNG Pulmonx Corporation	D-	39/100	—	74.2%	-35.0%	-5.05%	$135.9M	/lung-vs-krmd →
SKYA SkyAI Inc.	D-	42/100	—	-30.0%	-35.0%	+1.37%	$126.7M	/skya-vs-krmd →
STIM Neuronetics Inc.	E	30/100	—	48.5%	-35.0%	-5.46%	$181.3M	/stim-vs-krmd →
PYPD PolyPid Ltd.	D	44/100	—	—	-35.0%	-3.58%	$113.5M	/pypd-vs-krmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000704440

In its most recent audited fiscal period (FY2025, filed 2025-12-31), KORU Medical Systems Inc. (KRMD) reported GAAP revenue of $41.1M (+22.2% vs. FY2024 revenue of $33.6M , and +44.2% cumulative change since FY2023) , GAAP net income of -$2.6M, operating cash flow of $462.4K, and free cash flow of $462.4K (+244.6% YoY). On the balance sheet, KRMD closed FY2025 with $28.2M in total assets against $0 in total debt (Altman Z-Score: 8.05, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$41.1M	-$2.6M	$462.4K	$462.4K	$28.2M	—
FY2024 (FY)	2024-12-31	$33.6M	-$6.1M	-$319.7K	-$319.7K	$27.2M	—
FY2023 (FY)	2023-12-31	$28.5M	-$13.7M	-$4.9M	-$4.9M	—	—

3. KRMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KRMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does KRMD compare to LUNG and SKYA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for KRMD?

Where is KRMD trading relative to its 50-day, 200-day, and 52-week technical levels?

KRMD last traded at $2.99 (-7.43% on volume of 165,220 shares), positioning the stock -4.47% below its 50-day simple moving average ($3.13) and -25.44% below its 200-day simple moving average ($4.01). Across its 52-week range of $2.86 to $6.61, KRMD sits at the 3.5% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.2% ($2.71 to $3.27).

KRMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell KRMD stock right now?

KORU Medical Systems Inc. (KRMD) currently earns a Roarable Rating of D (Sell — SELL) with 45/100 RQD Confidence. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.

What is KRMD's 12-month price target and RQD AI Jury consensus?

KRMD's 12-month base price target is $2.82 (range $2.2 to $6.94), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: KRMD RQD Cockpit KRMD 12M Forecast KRMD Earnings & Move KRMD Dividends & DRIP KRMD Insiders & 13F KRMD Whale Options KRMD Profit Sankey KRMD News & Why

Sector Peer Dials

Apyx Medical Corporation

KRMD Core Snapshot

Market Cap $149.1M

Trailing / Fwd P/E — / —

Gross Profit Margin 62.3%

Return on Capital (ROIC) -28.7%

Free Cash Flow Yield 0.31%

12M Base Price Target $2.82

FREE TRADER TOOLS

Own KRMD Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With KRMD → 🏆 Trade KRMD in $100K Prop Arena →

KRMD Wire

Why It Moved →

Peer / Ecosystem Wire Yahoo Finance • 4h ago

KORU Medical Systems to Report Third Quarter 2026 Financial Results on November 10, 2026

Direct Company Event TradingView • 7h ago

KORU Medical Systems, Inc. Estimates – NASDAQ:KRMD

Peer / Ecosystem Wire Investing.com UK • 10h ago

Form 4 KORU Medical Systems Inc: Shahriar Matin (Director) For: 1 October

Direct Company Event https://www.siam.in/ • 13h ago

KORU Medical Systems (KRMD) Holds Steady at $3.02 as Shares Edge Higher - Volatility Smile

Peer / Ecosystem Wire Investing.com Canada • 16h ago

Form 4 KORU Medical Systems Inc For: 8 October By Investing.com

ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

KRMD — KORU Medical Systems Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:42:39Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 45 out of 100, graded D, with the verdict "Roarable Sell — Underperform / Distribution Warning" (per the Roarable RQD rating). The five pillars each carry a maximum of 20 points:

Fundamental Cash Engine: 10 / 20. Per the Roarable RQD rating, this reflects ROIC of -28.7% and an FCF yield of 0.31%. For an investor, this is the weakest-supported area: the business is not currently earning a return on invested capital, and free cash flow relative to market value is minimal.
Whale 13F Flow: 8 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is below the midpoint, indicating limited institutional conviction in the data provided. Holder-level detail is not available in source data.
Insider Conviction: 6 / 20. Per the Roarable RQD rating, this covers SEC Form 4 and Congressional PTR cluster flow. The score is weak, and the recent news wire does reference Form 4 filings by a director, but the transaction direction and size are not available in source data.
Macro Regime Fit: 5 / 20. Per the Roarable RQD rating, this reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 means the stock is expected to move in line with the broader market, offering no defensive cushion; this pillar scores lowest of the five.
Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, this is the strongest pillar, citing Altman Z of 8.05, Piotroski F of 7/9, and Debt/Equity of 0.5. This indicates the balance sheet is the company's main support, even as operations remain unprofitable.

Investor implications: The upside case rests mainly on the balance sheet's resilience and a possible turn in operating results; the source data does not establish a near-term earnings catalyst beyond the scheduled Q3 2026 report. The valuation tradeoff is that the market capitalization of $149.1M is set against negative operating margin (-7.2%) and negative ROIC (-28.7%), so the stock is not priced on current cash generation. The rating's "distribution warning" label, per the Roarable RQD rating, signals that the combined pillar profile is unfavorable overall.

Business

KORU Medical Systems Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry (per the SEC profile). The profile does not describe its products, customers, or revenue model in source data. Market capitalization is $0.1B per the profile. Revenue of $41.1M in FY 2025 is reported in the SEC financials, but the source data does not describe how the company generates that revenue.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$41.1M	$-3.0M	$-2.6M	N/A	$0.5M	$8.9M	N/A
FY 2024	$33.6M	$-6.4M	$-6.1M	N/A	$-0.3M	$9.6M	N/A
FY 2023	$28.5M	$-10.3M	$-13.7M	N/A	$-4.9M	N/A	N/A

Per the SEC financials, revenue rose from $28.5M in FY 2023 to $41.1M in FY 2025, and net loss narrowed from $-13.7M to $-2.6M over the same span. Per the market data, gross margin is 62.3%, operating margin is -7.2%, and net margin is -6.4%, and ROIC is -28.7%. Per the Roarable RQD rating, the Altman Z-Score is 8.05, the Piotroski F-Score is 7/9, and Debt/Equity is 0.5, reflecting a balance sheet the rating treats as relatively sound despite continued operating losses.

Recent Catalysts & News Wire Analysis

Scheduled catalyst: The company is set to report third quarter 2026 financial results on November 10, 2026 (per the news wire headline).
Insider filings: Multiple Form 4 filings are referenced in the news wire, including one by a director (Shahriar Matin) and filings dated 1 October and 8 October; transaction details are not available in source data.
Price action: A news wire item references shares holding near $3.02 and edging higher; the market data shows a price of $3.23 and a change of 0.31%.
Volume: Per the market data, volume was 84,326.
Proprietary signals: None are recorded in the Butterfly Supply-Chain Graph.
Risk watch: The news wire contains no explicit risk item beyond the Roarable rating's distribution warning; the wire items are primarily aggregator and summary reports, and several contain generic language without substantive detail.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations are therefore not available in source data. The sector and industry classification (Health Care; Medical/Dental Instruments) is the only contextual link provided. A prospective investor should note that the absence of mapped dependencies means second-order bottlenecks cannot be identified from the source data.

Open Questions

What are the company's products, customers, and revenue model, since the profile provides only sector and industry classification?
Why is EPS, P/E, and EV/EBITDA unavailable, and what share count would be needed to evaluate valuation against the $149.1M market capitalization?
What were the direction, size, and price of the Form 4 insider transactions referenced in the news wire?
What drove the negative ROIC of -28.7% and what is the path, if any, toward operating profitability?
What are the debt levels and terms, given that debt is reported as N/A in the SEC financials despite a Debt/Equity ratio of 0.5 in the rating data?

KRMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for KORU Medical Systems Inc. (KRMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KRMD Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 4h ago

KORU Medical Systems to Report Third Quarter 2026 Financial Results on November 10, 2026

Yahoo Finance report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 7h ago

KORU Medical Systems, Inc. Estimates – NASDAQ:KRMD

TradingView report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 10h ago

Form 4 KORU Medical Systems Inc: Shahriar Matin (Director) For: 1 October

Investing.com UK report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 13h ago

KORU Medical Systems (KRMD) Holds Steady at $3.02 as Shares Edge Higher - Volatility Smile

https://www.siam.in/ report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com Canada • 16h ago

Form 4 KORU Medical Systems Inc For: 8 October By Investing.com

Investing.com Canada report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 19h ago

Precision Optics Corporation (POCI) Stock Price, News & Analysis

Stock Titan report covering KORU Medical Systems Inc. (KRMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KRMD Bull vs. Bear Conversation Board — What's Your Call at $2.99?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KRMD 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.84 (-12.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is KRMD (D • RQD 45/100) a Buy at $3.23?

Welcome to the KRMD (KORU Medical Systems Inc.) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $2.68 (-17.0%)

Spot @ $3.23

Pump the brakes on KRMD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on KRMD, but look at what you are paying: current EV/EBITDA multiples with 62.3% gross margins. Unless KORU Medical Systems Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.71 (+14.9%)

Spot @ $3.23

KRMD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on KRMD, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $3.23 (52-wk range $2.86 - $6.61), any beat on forward guidance forces shorts and underweight funds to chase.